Arvinas, a biotech leader in New Haven, Connecticut, is renowned for innovative therapies aimed at combating serious diseases. The company announced a "mass layoff" affecting 131 employees, including 92 in…
Genenta Science is set to present at the 'Montalcini Global Biotech Tour' in Doha on April 17th, 2025, aiming to expand investment opportunities beyond traditional western markets. The firm secured…
Edesa Biotech announces Peter J. Weiler as the new CFO, signifying a strategic leadership shift. Weiler brings extensive experience in finance, biology, and business from his roles at Exzell Pharma,…
Edesa Biotech has announced a strategic leadership change, appointing Peter J. Weiler as Chief Financial Officer effective May 1, 2025. Weiler brings extensive experience from roles at Exzell Pharma, Biosyent…
Edesa Biotech undergoes a pivotal leadership change as Peter J. Weiler replaces Stephen Lemieux. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His…
Peter J. Weiler appointed as Chief Financial Officer of Edesa Biotech, succeeding Stephen Lemieux. Weiler's leadership experience includes roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His background is…
Wacker Biotech and RNAV8 Bio's collaboration advances mRNA-based therapies, merging manufacturing and mRNA engineering expertise. Wacker Biotech brings pharmaceutical-grade pDNA and protein production capabilities with high-capacity fermentation lines. RNAV8 Bio…
Abzena's global facilities are hubs of innovation in pharmaceutical development, led by CIO Dave Williamson. Williamson's diverse background, from the US Army to biotechnology, informs his approach to bioconjugate and…
Neurona Therapeutics is advancing allogeneic cell therapy for drug-resistant mesial temporal lobe epilepsy (MTLE) with its promising NRTX-1001 therapy. Supported by a $102 million financing round, Neurona is navigating the…
The FDA is undergoing significant changes, including major job reductions and administrative restructuring, which may impact its effectiveness. Peter Marks, a key figure in advancing gene and cell therapies, has…